Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers

Surowiak, Paweł; Materna, Verena; Győrffy, Balázs; Matkowski, Rafał; Wojnar, Andrzej; Maciejczyk, Adam; Paluchowski, Piotr; Dzięgiel, Piotr; Pudełko, Marek; Kornafel, Jan; Dietel, Manfred; Kristiansen, Glen; Zabel, Maciej; Lage, Hermann

doi:10.1038/sj.bjc.6603254

Cited by 49 publications

(55 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should also be emphasized that our patient cohort is well described and researched. The results of many analyses performed on this group (originally larger, approximately 100 cases, currently only 85 due to the usage of tissue material) were previously published (38)(39)(40).…”

Section: Discussionmentioning

confidence: 92%

Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node-negative early breast cancer: 15-year follow-up

Donizy

Pietrzyk²,

Hałoń

et al. 2014

Oncology Reports

View full text Add to dashboard Cite

Abstract. PARP-1 plays an important role in DNA damage repair and maintaining genome integrity by repairing DNA single-strand breaks (SSBs) by base excision repair (BER). The aim of the present study was to examine the expression of PARP-1 in breast cancer (BC) patients and to assess the relationship between the subcellular localization of this protein and clinicopathological characteristics. The reactivity of PARP-1 was analyzed by immunohistochemistry in a homogeneous group of 83 stage II ductal BC patients with a 15-year follow-up. Immunostaining of PARP-1 was also evaluated in 4 human BC cell lines and resistance prediction profile for 11 anticancer agents was performed using 3 models of drug-resistant cell lines. Nuclear-cytoplasmic expression (NCE) was associated with shorter overall survival, which was not statistically significant during the 10-year follow-up but became statistically significant after 10 years of observation, during the 15-year follow-up (P=0.015). Analysis performed in subgroups of patients with (N+) and without (N-) nodal metastases showed that NCE was associated with poor clinical outcome in N-patients (P=0.017). Multivariate analysis confirmed a significant impact of NCE on unfavorable prognosis in N-early BC. The presence of PARP-1 NCE may be a new potential unfavorable prognostic factor in lymph node-negative early BC.

show abstract

Section: Discussionmentioning

confidence: 92%

Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node-negative early breast cancer: 15-year follow-up

Donizy

Pietrzyk²,

Hałoń

et al. 2014

Oncology Reports

View full text Add to dashboard Cite

show abstract

“…In the last few years, a large body of literature has also implicated CD24 expression in tumourigenesis and in progression of several types of cancer [10,17]. Hence, CD24 has been identified as a new prognostic variable in ovarian cancer [8,25], breast [12,24], prostate [9] and colorectal adenocarcinoma [26], intrahepatic cholangiocarcinoma [23] as well as non-small cell lung cancer [11]. However, no significant impact on patient outcome was identified in pancreatic adenocarcinomas [4].…”

Section: Introductionmentioning

confidence: 95%

CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression

et al. 2006

View full text Add to dashboard Cite

Expression of the mucin-like adhesion molecule CD24 has been implicated in the progression of several types of cancer and has been identified as new prognostic factor. We evaluated CD24 expression in 268 consecutive cases of upper urinary tract urothelial carcinoma with respect to associations with tumour stage, grade, angioinvasion and infiltrative growth pattern using a tissue microarray technique and correlated data with patient outcome. CD24 expression was demonstrated in 161/259 (62%) evaluable tumours and was associated with high tumour stage [77/139 (55%) pTa/pT1 vs 84/120 (70%) pT2-pT4; P=0.02] and high tumour grade [68/139 (49%) low vs 93/120 (78%) high grade; P<0.001] as well as presence of angioinvasion (P=0.002) and infiltrative pattern of invasion (P=0.007). Patients with CD24-positive tumours tended to have a higher risk of disease progression (P=0.065). Multivariate analysis, however, proved pT stage >1 [P<0.001, risk ratio (RR)=5.87, 95% confidence interval (CI)=2.88-11.95] and high tumour grade (P<0.001, RR=3.30, 95% CI 1.75-6.22) as only independent predictors of metastatic disease. In conclusion, CD24 expression in upper urinary tract urothelial cancer is associated with advanced tumour stage and high tumour grade as well as histopathological features indicative of aggressive tumour behaviour, but it lacks independent impact on patient outcome.

show abstract

“…Although molecular markers like expression of estrogen and growth factor receptors, pS2, metallothionein, CD24, cathepsin D, ERBB2, and mutations in the TP53 gene all have been correlated to breast cancer prognosis, the use of single marker provides limited information for the prognosis of an individual patient [1,2]. In view of the molecular heterogeneity of breast tumors and the large number of marker genes involved, studying multiple genetic alterations simultaneously is of utmost importance.…”

Section: Introductionmentioning

confidence: 99%

Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients

Győrffy

Schäfer

2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

The transcriptome of breast cancers have been extensively screened with microarrays and large sets of genes associated with clinical features have been established. The aim of this study was to validate original gene sets on a large cohort of raw breast cancer microarray data with known clinical follow-up. We recovered 20 publications and matched them to Affymetrix HGU133A annotations. Raw Affymetrix HGU133A microarray data were extracted from GEO and MAS5 normalized. For classifying patients using the selected gene sets, we applied prediction analysis of microarrays and constructed KaplanMeier plots. A new classification including all patients was generated using supervised principal components analysis. Seven studies including 1,470 patients were downloaded from GEO. Notably, we uncovered 641 microarrays representing 251 individual tumor specimens among them, which were repeatedly described under independent GEO identifiers. We excluded all redundant data and used the remaining 1,079 samples. Eight of the 20 gene sets were able to predict response at a significance of P \ 0.05. The discrimination of good and poor prognosis groups exclusively relying on gene expression data resulted in high significance (P = 1.8E-12). A model including genes fitted by both gene expression and clinical covariates (lymph node status and grade) contains 44 genes and can predict response at P = 9.5E-7. The outcome provides a ranking of the gene lists regarding applicability on an independent dataset. We established a consensus predictor combining the available clinical and gene expression data. The database comprising expression profiles of 1,079 breast cancers can be used to classify individual patients.

show abstract

Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers

Cited by 49 publications

References 17 publications

Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node-negative early breast cancer: 15-year follow-up

Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node-negative early breast cancer: 15-year follow-up

CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression

Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients

Contact Info

Product

Resources

About